glp-1 by ro Inside Serena Williams' partnership with for GLP-1s The first ever FDA-approved GLP-1

At week 12, both groups presented with a significant relative reduction in CAP (48.7 dB/m, 95% CI 40.8, 57.0, P -0.6), 40% (n=6) of exercise subjects achieved this threshold while no standard of care subject met this difference

Psychiatric adverse events associated with GLP-1 receptor agonists: A real-world pharmacovigilance study based on the FDA adverse event reporting system database

The authors speculate that this could be due to off-label prescribing or individuals acquiring medications through non-medical routes such as online purchases

Glucagon-like peptide 1 receptor agonists and risk of diabetic retinopathy complications: cohort study in nationwide registers from two countries

Tirzepatide | Drugs BNF NICE

population, we found no evidence that GLP-1 RA use increases the risk of NAIONand in those with diabetes, we observed a lower risk